August 09, 2011

Jenner & Block Partner John J. Molenda will present “The Biologics Act: Impact on Regulatory Success of Follow-On Biologics,” during Canaccord Genuity’s “31st Annual Growth Conference,” being held on August 9 - 11, 2011, in Boston, MA.  Dr. Molenda will discuss the Biologics Act, the FDA hearings concerning implementation of the Act, and the wide-ranging implications of the Act on brand and generic pharmaceutical companies. 

This conference brings together some of the world’s most innovative companies and institutional investors to share knowledge, discuss emerging trends, build relationships, identify opportunities and ignite global ideas for growth.  There are over 200 companies presenting at the conference in the Technology, Life Sciences, Real Estate, Consumer, and Sustainability sectors.

Dr. Molenda is a member of the Firm’s Litigation Department and the Patent Litigation & Counseling, Appellate and Supreme Court, and Pharmaceutical, Biotech and Medical Devices Practices.  He has extensive experience in litigating cases in the pharmaceutical and biotech fields, having litigated numerous Hatch-Waxman and non-Hatch-Waxman cases on behalf of both brand and generic companies and represented clients in litigating patents involving genetic engineering, molecular biology, and cell biology-related inventions.  

Please click here for additional information.